|Articles|August 1, 2000

New Advances in the Treatment of Type 2 Diabetes: Clinical and Economic Implications for Managed Car
Volume 6
Issue 13 Suppl

Hyperlipidemia and Cardiovascular Risk Factors in Patients with Type 2 Diabetes

Author(s)Ronald Goldberg, MD

Download PDF: Hyperlipidemia and Cardiovascular Risk Factors in Patients with Type 2 Diabetes

Articles in this issue

about 26 years ago

Article

Participating Faculty

about 26 years ago

Article

Introduction

about 26 years ago

Article

The Clinical Implications of Insulin Resistance

about 26 years ago

Article

Cost-Effective Management of Type 2 Diabetes: Providing Quality in a Cost-Constrained Environment

about 26 years ago

Article

Thiazolidiones in the Treatment of Type 2 Diabetes: A Clinician's Perspective

about 26 years ago

Article

Selected Abstracts

about 26 years ago

Article

CME/CPE Quiz

about 26 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Hyperlipidemia and Cardiovascular Risk Factors in Patients with Type 2 Diabetes

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug

Sarcoma Gene Signature May Predict Who Benefits From Pazopanib

Lifestyle Factors Offer Actionable Targets in MASLD Management: Zobair M. Younossi, MD

Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care

GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis